Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1324-1331

  Takahashi, Yusuke ^a,b   Horio, Hirotoshi ^a   Hato, Tai ^a   Harada, Masahiko ^a   Matsutani, Noriyuki ^b   Morita, Satoshi ^c   Kawamura, Masafumi ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; LABORATORY TEST; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREOPERATIVE CARE; PREOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; LUNG NEOPLASMS; LYMPHOCYTE; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUTROPHILS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE;

EID: 84952875212     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4735-5     Document Type: Article

References (30)

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49–52.
2. Asamura H, Goya T, Koshiishi Y; Japanese Joint Committee of Lung Cancer Registry, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52.
3. Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013;114:149–54.
4. Mallappa S, Sinha A, Gupta S, Chadwick SJ. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013;15:323–8.
5. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108:901–7.
6. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M. A derived neutrophil and lymphocyte ratio predicts survival in patients with various cancer. Br J Cancer. 2012;107:695–9.
7. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:425–8.
8. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012;32:3535–8.
9. Rami-Porta R, Wittekind C, Goldstraw P; International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25–33.
10. Travis WD, Brambilla W, Mueller-Hermelink HK, Harris CC. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon (2004).
11. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:985.
12. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606–12.
13. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659:15–30.
14. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184–90.
15. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997;11:457–65.
16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–44.
17. Jilma B, Blann A, Pernerstorfer T, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med. 1999;159:857–63.
18. Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small cell lung cancer: an analysis of Japan Multinational Atrial Organization LC00-03. Eur J Cancer. 2009;45:1950–8.
19. Roxburg CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.
20. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and cancer. Cell. 2010;140:883–99.
21. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s role in cancer suppression and promotion. Science. 2011;331:1565–70.
22. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small lung cancer. Clin Cancer Res. 2011;17:5347–56.
23. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict critical outcome. Science. 2008;313:1960–4.
24. Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009;10:877–84.
25. Swan JB, Smyth MJ. Immune and surveillance of tumors. J Clin Invest. 2007;117:1137–46.
26. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709–17.
27. Kadota K, Yeh YC, Villena-Vargas J, et al. Tumor budding correlates with protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest. 2015. doi: 10.1378/chest.14-3005.
28. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31:490–8.
29. Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma; Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14:822–7.
30. Hamada C, Tsuboi M, Ohta M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol. 2009;4:1511–6.